Evotec AG (EVTG.DE)

EVTG.DE on Xetra

3.64EUR
15 Aug 2014
Price Change (% chg)

€-0.11 (-2.86%)
Prev Close
€3.75
Open
€3.74
Day's High
€3.77
Day's Low
€3.64
Volume
670,696
Avg. Vol
646,866
52-wk High
€4.57
52-wk Low
€2.42

EVTG.DE

Chart for EVTG.DE

About

Evotec AG is a Germany-based parent company of the Evotec group, which is engaged in drug discovery and development company focused on providing integrated drug discovery services and alliances to the pharmaceutical and biotechnology industry. In addition, the Company has a small number of its own drug candidates at various... (more)

Overall

Beta: 0.68
Market Cap (Mil.): €406.92
Shares Outstanding (Mil.): 131.69
Dividend: --
Yield (%): --

Financials

  EVTG.DE Industry Sector
P/E (TTM): -- 269.72 39.20
EPS (TTM): -0.22 -- --
ROI: -14.45 -1.77 17.16
ROE: -17.14 -3.18 18.09
Search Stocks

BRIEF-Evotec says will take legal steps after Hyperion setback

* news: evotec reports results of the first nine months of 2014

12 Nov 2014

BRIEF-Evotec hits milestone in Bayer Healthcare alliance

Sept 30 - Evotec AG : * Says Evotec receives milestone as part of its multi-target alliance with

30 Sep 2014

BRIEF-Evotec and partners awarded public grants to develop MS drugs

Sept 24 - Evotec AG : * Says it and its partners were awarded public grants to develop new drug

24 Sep 2014

BRIEF-Evotec extends collaboration with CHDI on Huntington's

Sept 11 - Evotec AG : * Says Evotec and CHDI foundation extend ongoing collaboration to fight

11 Sep 2014

Evotec profit target in danger after drug trial halted

BERLIN - German biotechnology company Evotec may miss its profit target for 2014 after a trial involving a drug for which it expected to receive royalties was halted.

08 Sep 2014

UPDATE 1-Evotec profit target in danger after drug trial halted

BERLIN, Sept 8 - German biotechnology company Evotec may miss its profit target for 2014 after a trial involving a drug for which it expected to receive royalties was halted.

08 Sep 2014

Evotec takes charge for end of diabetes drug development

BERLIN, Sept 8 - German biotechnology company Evotec said on Monday it would take an impairment charge of 8.7 million euros ($11.3 million) after one of its advanced projects, diabetes drug Diapep277, was terminated.

08 Sep 2014

BRIEF-Evotec, Medicines for Malaria venture announce collaboration

Aug 19 - Evotec AG : * Says Evotec and medicines for malaria venture announce a long-term compound

19 Aug 2014

BRIEF-Evotec shares rise 3.2 percent in early trade after Q2 results

Aug 12 - Evotec AG : * Shares rise 3.2 percent in early trade after Q2 results

12 Aug 2014

BRIEF-Evotec says receives first milestones in targetad collaboration

July 30 - Evotec AG : * Says receives first milestones in TargetAD collaboration Source text for Eikon:

30 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Alpha Deal Group Intelligence Brief
$50.00
Provider: Alpha Deal Group Intelligence Brief
$50.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks